Improving cancer immunotherapy through nanotechnology

Area of Science:

• Oncology
• Immunology
• Nanotechnology
• Bioengineering
• Drug Delivery

Background:

• Cancer immunotherapy, recognized by the 2018 Nobel Prize, harnesses the patient's immune system against tumors.
• Current immunotherapies have modest response rates (~15%) due to tumor immune evasion mechanisms.
• The spatiotemporal control of the immune system suggests therapies should also be spatiotemporally controlled for optimal therapeutic index.

Purpose of the Study:

• To explore how nanotechnology and related approaches can enhance cancer immunotherapy.
• To investigate methods for augmenting both endogenous and adoptively transferred immune cells.
• To address limitations in current cancer immunotherapy through rational, deductive design.

Main Methods:

• Utilizing nanoparticles and biomaterials to program the location, pharmacokinetics, and co-delivery of immunomodulatory compounds.
• Leveraging the convergence of nanotechnology, bioengineering, and drug delivery with cancer immunotherapy.
• Informing specificity, influencing localization, and improving the function of immune cells.

Main Results:

• Nanoparticles and biomaterials enable precise control over immunomodulatory compound delivery, surpassing traditional solution-based administration.
• This approach allows for tailored immune responses that cannot be achieved with conventional methods.
• The synergistic integration of multiple scientific fields facilitates addressing unmet needs in cancer treatment.

Conclusions:

• Nanotechnology and related approaches offer a rational strategy to overcome tumor immune evasion and improve immunotherapy efficacy.
• Precise spatiotemporal control via nanomaterials can significantly enhance the therapeutic index of immunomodulatory agents.
• The convergence of advanced fields promises to significantly improve outcomes for patients undergoing cancer immunotherapy.